NAD+, NMN and nicotinamide: three different molecules, one marketing word

“NAD” is now a category label rather than a molecule, and the imprecision is doing real work in this market. Three different compounds get sold under it, and they are not interchangeable.

The three molecules

NAD+ (nicotinamide adenine dinucleotide) is the coenzyme itself — the electron carrier every cell uses in redox reactions and the substrate that sirtuins and PARPs consume. Cellular NAD+ declines with age; that observation is the whole basis of the field.

NMN (nicotinamide mononucleotide) is a direct biosynthetic precursor of NAD+. Its availability is a rate-limiting step in the salvage pathway, which is why it, rather than NAD+ itself, is what most human research administers.

Nicotinamide is a form of vitamin B3, further upstream, and a much older and cheaper molecule.

Our catalog lists what each product actually is: the item labelled NAD+ (Nicotinamide) is nicotinamide, the NMN item is nicotinamide mononucleotide, and Everlong is a combination that includes an NAD component with glutathione and resveratrol. Read the parenthesis on the label — across this market it is the only thing that tells you which molecule you are getting.

The human trial that exists

One randomised, placebo-controlled, double-blind trial anchors the field, published in Science in 2021 (Yoshino et al.):

• Population: postmenopausal women with prediabetes, overweight or obese
• Intervention: oral NMN, 250 mg/day, for 10 weeks
• Primary finding: muscle insulin sensitivity increased — roughly a 25% improvement in muscle glucose disposal — versus placebo, with changes in insulin signalling and muscle tissue remodelling

That is a real, positive, properly controlled result. It is also narrow: one small trial, one precursor, one dose, one population, ten weeks, and a metabolic endpoint rather than anything to do with ageing, energy or longevity. The paper drew a published technical comment and a response from the authors — normal scientific process, worth reading alongside the original if you care about the strength of the finding.

Notably, body weight, blood pressure, lipids, liver fat and other whole-body measures did not significantly change. The effect was tissue-specific.

What is not established

• That NAD+ administered directly does what a precursor does. The coenzyme is not efficiently taken up intact by cells, which is precisely why precursors are the research route.
• That any of it extends healthspan or lifespan in humans. That claim rests on model organisms, not on trials.
• Long-term safety at any dose. The 2021 trial ran ten weeks.

Why this matters for a supplier

It is the easiest category in this catalog to sell dishonestly — the words “NAD” and “longevity” do most of the work by themselves, and almost nobody checks which molecule is in the vial. The mechanism is genuinely well described; the human outcome data amounts to one small trial. Both halves of that sentence belong on the page.

If your interest is mitochondrial function more broadly, MOTS-c approaches the same organelle from a different direction, with a similar evidence gap between mechanism and human outcomes.

What we supply

NAD+ (Nicotinamide) 100 mg and 200 mg, NMN 1500 mg/3 ml, and the Everlong combination — Nordic Peptides, shipped as supplied by the manufacturer, batch documentation on request. Research use only — not for human or veterinary use.